Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03118947 · ClinicalTrials.gov registry record · Phase 2
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
A Phase 2 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT03118947 is a Phase 2 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 79 participants.
The verdict
NCT03118947, a Phase 2 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of pimavanserin over 52 weeks of treatment in subjects with probable AD who have symptoms of agitation and aggression
Interventions
- DRUG Pimavanserin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2019-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03118947
The ClinicalTrials.gov registry entry for NCT03118947 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pimavanserin is the first listed.
NCT03118947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03118947 about?
NCT03118947 is a clinical study titled "A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease". To evaluate the safety and tolerability of pimavanserin over 52 weeks of treatment in subjects with probable AD who have symptoms of agitation and aggression
What is the current status of trial NCT03118947?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2017-02-23. Estimated completion is 2019-02-25.
What interventions are being tested in trial NCT03118947?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT03118947?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.